Patent intelligence · US
US 10188739
Compositions and methods for administering insulin or insulin-like protein to the brain
Compositions and methods for administering insulin or insulin-like protein to the brain
Patent details — US 10188739
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 29, 2019
- Expiration
- Jan 24, 2039
- Applicant
- XENETIC BIOSCIENCES, INC.
- Claims
- 19
- CPC classes
- A61K, A61K38/28, A61K47/61, A61K9/0043
Quick answer
US 10188739 (Compositions and methods for administering insulin or insulin-like protein to the brain) is held by XENETIC BIOSCIENCES, INC.. Status: granted. Granted Jan 29, 2019. Expires Jan 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- XENETIC BIOSCIENCES, INC.
- Grant date
- Expiration
- Claims
- 19
- CPC classes
- A61K, A61K38/28, A61K47/61, A61K9/0043
Frequently asked questions
What is US patent 10188739?
US 10188739 (Compositions and methods for administering insulin or insulin-like protein to the brain) is held by XENETIC BIOSCIENCES, INC.. Status: granted. Granted Jan 29, 2019. Expires Jan 24, 2039 (13 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10188739?
XENETIC BIOSCIENCES, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1 pharmaceutical patents for this assignee.
When does US 10188739 expire?
Our index shows an expiration date of Jan 24, 2039 (13 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.